niclosamide has been researched along with Cancer of Prostate in 8 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Roughly 268,000 new cases of prostate cancer and 34,000 deaths from prostate cancer are projected by the American Cancer Society to occur in the United States in 2022." | 1.72 | Synthesis and biological evaluation of niclosamide PROTACs. ( Chen, G; Chen, QH; Hang, J; Hossain, A; Lee, T; Munoz, E; Oceguera Nava, E; Wang, G; Wu, S; Zhang, Q, 2022) |
| "Niclosamide has the potential to target the IL6-Stat3-AR pathway to overcome enzalutamide resistance and inhibit migration and invasion in advanced prostate cancer." | 1.42 | Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. ( Armstrong, C; Evans, CP; Gao, AC; Liu, C; Lou, W; Zhu, Y, 2015) |
| "Salinomycin inhibited the growth of prostate cancer cells, but did not affect non-malignant prostate epithelial cells." | 1.38 | Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. ( Hilvo, M; Hyötyläinen, T; Iljin, K; Kallioniemi, O; Ketola, K; Orešič, M; Ruskeepää, AL; Vuoristo, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Munoz, E | 1 |
| Chen, G | 1 |
| Hossain, A | 1 |
| Wu, S | 1 |
| Oceguera Nava, E | 1 |
| Hang, J | 1 |
| Lee, T | 1 |
| Zhang, Q | 1 |
| Wang, G | 1 |
| Chen, QH | 1 |
| Jannu, AK | 1 |
| Puppala, ER | 1 |
| Gawali, B | 1 |
| Syamprasad, NP | 1 |
| Alexander, A | 1 |
| Marepally, S | 1 |
| Chella, N | 1 |
| Gangasani, JK | 1 |
| Naidu, VGM | 1 |
| Liu, C | 2 |
| Armstrong, CM | 1 |
| Lou, W | 2 |
| Lombard, AP | 1 |
| Cucchiara, V | 1 |
| Gu, X | 1 |
| Yang, JC | 1 |
| Nadiminty, N | 1 |
| Pan, CX | 1 |
| Evans, CP | 2 |
| Gao, AC | 2 |
| Wach, S | 1 |
| Taubert, H | 1 |
| Cronauer, M | 1 |
| Armstrong, C | 1 |
| Zhu, Y | 1 |
| Circu, ML | 1 |
| Dykes, SS | 1 |
| Carroll, J | 1 |
| Kelly, K | 1 |
| Galiano, F | 1 |
| Greer, A | 1 |
| Cardelli, J | 1 |
| El-Osta, H | 1 |
| Lu, W | 1 |
| Lin, C | 1 |
| Roberts, MJ | 1 |
| Waud, WR | 1 |
| Piazza, GA | 1 |
| Li, Y | 1 |
| Ketola, K | 1 |
| Hilvo, M | 1 |
| Hyötyläinen, T | 1 |
| Vuoristo, A | 1 |
| Ruskeepää, AL | 1 |
| Orešič, M | 1 |
| Kallioniemi, O | 1 |
| Iljin, K | 1 |
1 review available for niclosamide and Cancer of Prostate
| Article | Year |
|---|---|
Role of androgen receptor splice variants, their clinical relevance and treatment options.
Topics: Alternative Splicing; Androgen Antagonists; Androstadienes; Antineoplastic Agents, Hormonal; Benzami | 2020 |
7 other studies available for niclosamide and Cancer of Prostate
| Article | Year |
|---|---|
Synthesis and biological evaluation of niclosamide PROTACs.
Topics: Humans; Ligands; Male; Niclosamide; Prostatic Neoplasms; Proteolysis; Receptors, Androgen; Ubiquitin | 2022 |
Lithocholic acid-tryptophan conjugate (UniPR126) based mixed micelle as a nano carrier for specific delivery of niclosamide to prostate cancer via EphA2 receptor.
Topics: Cell Line, Tumor; Humans; Lithocholic Acid; Male; Micelles; Niclosamide; Prostatic Neoplasms; Recept | 2021 |
Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, | 2017 |
Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; D | 2015 |
A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion.
Topics: Antinematodal Agents; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Proliferation; Drug Screen | 2016 |
Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; beta Catenin; Breast Neoplasms; Cell Line, Tumor; C | 2011 |
Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress.
Topics: Aldehyde Dehydrogenase; Blotting, Western; Cell Division; Cell Line, Tumor; Cell Movement; Humans; M | 2012 |